Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biogen Lowers FY2025 Adj EPS Guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 Est

Author: Benzinga Newsdesk | October 30, 2025 05:53am

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. Increased expected full year 2025 total revenue to be approximately flat to increasing 1%, at constant currency, versus full year 2024, up from approximately flat previously.

Posted In: BIIB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist